SE453504B - N-metyl-d-glukaminsalt av 3,4-dihydro-5-metyl-6-(2-metylpropyl)-4-oxotieno(2,3-d)-pyrimidin-2-karboxylsyra och farmaceutisk komposition innehallande detta salt - Google Patents

N-metyl-d-glukaminsalt av 3,4-dihydro-5-metyl-6-(2-metylpropyl)-4-oxotieno(2,3-d)-pyrimidin-2-karboxylsyra och farmaceutisk komposition innehallande detta salt

Info

Publication number: SE453504B
Authority: SE; Sweden
Prior art keywords: methyl; salt; glucamine; methylpropyl; dihydro
Prior art date: 1981-08-21

Application number

SE8204792A

Other languages

English (en)

Swedish (sv)

Other versions

SE8204792D0 (sv

SE8204792L (sv

Inventor

A A Larsen

D A Owens

Original Assignee

Bristol Myers Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-08-21

Filing date

1982-08-20

Publication date

1988-02-08

1982-08-20 Application filed by Bristol Myers Co filed Critical Bristol Myers Co

1982-08-20 Publication of SE8204792D0 publication Critical patent/SE8204792D0/xx

1983-02-22 Publication of SE8204792L publication Critical patent/SE8204792L/xx

1988-02-08 Publication of SE453504B publication Critical patent/SE453504B/sv

Links

MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 title claims description 10
KTOQRRDVVIDEAA-UHFFFAOYSA-N 2-methylpropane Chemical class [CH2]C(C)C KTOQRRDVVIDEAA-UHFFFAOYSA-N 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
150000003839 salts Chemical class 0.000 claims description 30
239000000243 solution Substances 0.000 claims description 19
239000007864 aqueous solution Substances 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
238000000034 method Methods 0.000 claims description 3
239000000725 suspension Substances 0.000 claims description 3
WIZAMTSKPRSWIL-UHFFFAOYSA-N tiprinast Chemical compound N1=C(C(O)=O)NC(=O)C2=C1SC(CC(C)C)=C2C WIZAMTSKPRSWIL-UHFFFAOYSA-N 0.000 claims description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
206010045240 Type I hypersensitivity Diseases 0.000 claims description 2
230000001476 alcoholic effect Effects 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
231100000344 non-irritating Toxicity 0.000 claims description 2
239000002904 solvent Substances 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims 2
210000004400 mucous membrane Anatomy 0.000 claims 1
ZFCHNZDUMIOWFV-UHFFFAOYSA-N pyrimidine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-N 0.000 claims 1
239000000376 reactant Substances 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 14
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
-1 amine salt Chemical class 0.000 description 6
239000000203 mixture Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
238000011065 in-situ storage Methods 0.000 description 4
239000000843 powder Substances 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000003756 stirring Methods 0.000 description 3
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000000470 constituent Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
OPEPFDHEYUYTMO-WZTVWXICSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol;5-methyl-6-(2-methylpropyl)-4-oxo-3h-thieno[2,3-d]pyrimidine-2-carboxylic acid Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.N1=C(C(O)=O)NC(=O)C2=C1SC(CC(C)C)=C2C OPEPFDHEYUYTMO-WZTVWXICSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
CDMIETFBAJYVHS-UHFFFAOYSA-L O.CC1=C(SC=2N=C(NC(C21)=O)C(=O)[O-])CC(C)C.[K+].[K+].CC2=C(SC=1N=C(NC(C12)=O)C(=O)[O-])CC(C)C Chemical compound O.CC1=C(SC=2N=C(NC(C21)=O)C(=O)[O-])CC(C)C.[K+].[K+].CC2=C(SC=1N=C(NC(C12)=O)C(=O)[O-])CC(C)C CDMIETFBAJYVHS-UHFFFAOYSA-L 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000000043 antiallergic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
150000001721 carbon Chemical class 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000446 fuel Substances 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940067107 phenylethyl alcohol Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
239000008213 purified water Substances 0.000 description 1
229940001607 sodium bisulfite Drugs 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicinal Preparation (AREA)

SE8204792A 1981-08-21 1982-08-20 N-metyl-d-glukaminsalt av 3,4-dihydro-5-metyl-6-(2-metylpropyl)-4-oxotieno(2,3-d)-pyrimidin-2-karboxylsyra och farmaceutisk komposition innehallande detta salt SE453504B (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US06/294,962 US4377583A (en)	1981-08-21	1981-08-21	N-Methyl-D-glucamine salt of with 3,4-dihydro-5-methyl-6-(2-methylpropyl)-4-oxothieno[2,3-d]pyrimidine-2-carboxylic acid

Publications (3)

Publication Number	Publication Date
SE8204792D0 SE8204792D0 (sv)	1982-08-20
SE8204792L SE8204792L (sv)	1983-02-22
SE453504B true SE453504B (sv)	1988-02-08

Family

ID=23135663

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8204792A SE453504B (sv)	1981-08-21	1982-08-20	N-metyl-d-glukaminsalt av 3,4-dihydro-5-metyl-6-(2-metylpropyl)-4-oxotieno(2,3-d)-pyrimidin-2-karboxylsyra och farmaceutisk komposition innehallande detta salt

Country Status (23)

Country	Link
US (1)	US4377583A (it)
JP (1)	JPS5843976A (it)
KR (1)	KR870001240B1 (it)
AT (1)	AT381314B (it)
AU (1)	AU558004B2 (it)
BE (1)	BE894162A (it)
CA (1)	CA1224465A (it)
CH (1)	CH651569A5 (it)
DE (1)	DE3231103A1 (it)
DK (1)	DK164059C (it)
ES (1)	ES515156A0 (it)
FI (1)	FI74965C (it)
FR (1)	FR2511680B1 (it)
GB (1)	GB2104521B (it)
GR (1)	GR76250B (it)
IE (1)	IE53804B1 (it)
IT (1)	IT1149064B (it)
LU (1)	LU84346A1 (it)
MY (1)	MY8800122A (it)
NL (1)	NL8203280A (it)
PT (1)	PT75446A (it)
SE (1)	SE453504B (it)
ZA (1)	ZA826019B (it)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5753701A (en) *	1996-10-25	1998-05-19	University Of Kentucky	N-chloro-N-methyl glucamine and N-chloro-N-methyl glucamine esters as novel safe agents for water disinfection
RU2387665C2 (ru) *	2004-03-17	2010-04-27	Панакос Фармасьютикалз, Инк.	Фармацевтические соли 3-о-(3', 3'-диметилсукцинил)бетулиновой кислоты
US11571431B2 (en) *	2013-12-04	2023-02-07	Galmed Research And Development Ltd	Aramchol salts
EP3781155A4 (en) *	2018-04-17	2021-10-06	Cardurion Pharmaceuticals, LLC	THIENOPYRIMIDINE MEGLUMINE SALTS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4054656A (en) *	1975-09-10	1977-10-18	Mead Johnson & Company	Thieno[2,3-d]pyrimidine antiallergic agents

1981
- 1981-08-21 US US06/294,962 patent/US4377583A/en not_active Expired - Fee Related
1982
- 1982-08-12 GR GR69028A patent/GR76250B/el unknown
- 1982-08-18 JP JP57142228A patent/JPS5843976A/ja active Granted
- 1982-08-18 ZA ZA826019A patent/ZA826019B/xx unknown
- 1982-08-19 AU AU87430/82A patent/AU558004B2/en not_active Ceased
- 1982-08-19 PT PT75446A patent/PT75446A/pt not_active IP Right Cessation
- 1982-08-19 DK DK372282A patent/DK164059C/da not_active IP Right Cessation
- 1982-08-19 CA CA000409740A patent/CA1224465A/en not_active Expired
- 1982-08-19 IT IT49006/82A patent/IT1149064B/it active
- 1982-08-20 LU LU84346A patent/LU84346A1/fr unknown
- 1982-08-20 IE IE2017/82A patent/IE53804B1/en not_active IP Right Cessation
- 1982-08-20 FI FI822907A patent/FI74965C/fi not_active IP Right Cessation
- 1982-08-20 GB GB08224025A patent/GB2104521B/en not_active Expired
- 1982-08-20 FR FR8214406A patent/FR2511680B1/fr not_active Expired
- 1982-08-20 ES ES515156A patent/ES515156A0/es active Granted
- 1982-08-20 SE SE8204792A patent/SE453504B/sv not_active IP Right Cessation
- 1982-08-20 BE BE0/208853A patent/BE894162A/fr not_active IP Right Cessation
- 1982-08-20 KR KR8203744A patent/KR870001240B1/ko not_active IP Right Cessation
- 1982-08-20 NL NL8203280A patent/NL8203280A/nl not_active Application Discontinuation
- 1982-08-20 DE DE19823231103 patent/DE3231103A1/de active Granted
- 1982-08-23 AT AT0318382A patent/AT381314B/de not_active IP Right Cessation
- 1982-08-23 CH CH5001/82A patent/CH651569A5/de not_active IP Right Cessation
1988
- 1988-12-30 MY MY122/88A patent/MY8800122A/xx unknown

Also Published As

Publication number	Publication date
FI74965C (fi)	1988-04-11
GB2104521B (en)	1985-05-22
FI74965B (fi)	1987-12-31
DE3231103C2 (it)	1990-10-04
MY8800122A (en)	1988-12-31
DK164059C (da)	1992-09-28
AU558004B2 (en)	1987-01-15
KR870001240B1 (ko)	1987-06-26
SE8204792D0 (sv)	1982-08-20
US4377583A (en)	1983-03-22
IE53804B1 (en)	1989-03-01
ES8401074A1 (es)	1983-12-01
AU8743082A (en)	1983-02-24
FR2511680B1 (fr)	1985-12-27
IT8249006A0 (it)	1982-08-19
DK372282A (da)	1983-02-22
CA1224465A (en)	1987-07-21
LU84346A1 (fr)	1983-06-07
ES515156A0 (es)	1983-12-01
IE822017L (en)	1983-02-21
FR2511680A1 (fr)	1983-02-25
FI822907L (fi)	1983-02-22
DK164059B (da)	1992-05-04
AT381314B (de)	1986-09-25
JPS5843976A (ja)	1983-03-14
JPH0476995B2 (it)	1992-12-07
SE8204792L (sv)	1983-02-22
DE3231103A1 (de)	1983-03-10
ZA826019B (en)	1983-07-27
PT75446A (en)	1982-09-01
ATA318382A (de)	1986-02-15
GB2104521A (en)	1983-03-09
NL8203280A (nl)	1983-03-16
BE894162A (fr)	1983-02-21
IT1149064B (it)	1986-12-03
CH651569A5 (de)	1985-09-30
FI822907A0 (fi)	1982-08-20
GR76250B (it)	1984-08-04
KR840001178A (ko)	1984-03-28

Publication	Publication Date	Title
HUT45236A (en)	1988-06-28	Process for producing new benzimidazole derivatives
IL28200A (en)	1972-02-29	S-triazine compounds and their production
EP1606290A1 (en)	2005-12-21	Weak base salts
SU1739845A3 (ru)	1992-06-07	Способ получени производных изоиндолинона или их солей
SE453504B (sv)	1988-02-08	N-metyl-d-glukaminsalt av 3,4-dihydro-5-metyl-6-(2-metylpropyl)-4-oxotieno(2,3-d)-pyrimidin-2-karboxylsyra och farmaceutisk komposition innehallande detta salt
AU599034B2 (en)	1990-07-12	Furosemide salts
ATE19627T1 (de)	1986-05-15	Substituierte pyrimidin-2-one, ihre salze, verfahren zu deren herstellung und diese enthaltende zusammensetzungen.
EP0028336B1 (en)	1983-10-26	Derivative of creatinol-o-phosphate having therapeutical action, process for the preparation thereof and related pharmaceutical compositions
US5231095A (en)	1993-07-27	S-timolol hemihydrate
JPS5726692A (en)	1982-02-12	Preparation of stable crystal of salt of ceftizoxime
JPS61180771A (ja)	1986-08-13	安定な抗バクテリア剤水溶液
ES8201140A1 (es)	1981-12-01	Procedimiento para la preparacion de 2-fenilamino-imidazoli nas-(2)sustituidas.
JPS595575B2 (ja)	1984-02-06	ヒドロキシルアミンの安定化剤
JPH02250896A (ja)	1990-10-08	３―ピログルタミル―チアゾリジン―４―カルボン酸誘導体
SI9620056A (sl)	1998-04-30	Postopek priprave oblike 1 ranitidin hidroklorida
PT86215B (pt)	1990-11-07	Processo para a preparacao de novos derivados de isoindole
US3592902A (en)	1971-07-13	Injection
JP2012521433A (ja)	2012-09-13	フルオロキノロンカルボン酸分子結晶
US3760086A (en)	1973-09-18	Tranquilizer
RU2091382C1 (ru)	1997-09-27	Производные 4-ацетил-имидазо(4,5-в)индол-2-тиона, обладающие противогипоксической активностью и вирусингибирующей активностью в отношении вируса венесуэльского энцефаломиелита лошадей и способ их получения
US2085064A (en)	1937-06-29	Aromatic mercury cyclic alkaloid compounds and method of making them
KR820001615B1 (ko)	1982-09-11	N-펜에틸 아세트아미드 화합물의 제조방법
CN103288664A (zh)	2013-09-11	一种新的bapta衍生物、其制备方法及其医药用途
SE453497B (sv)	1988-02-08	Antitumormedel och kompositioner pa basis derav samt forfarande for framstellning av dessa kompositioner
JPH01128985A (ja)	1989-05-22	薬物動態学的に改良されたセファロスポリン誘導体、その製法、それを含む医薬組成物、及び成中間体

Legal Events

Date	Code	Title	Description
1995-01-31	NAL	Patent in force	Ref document number: 8204792-9 Format of ref document f/p: F
1995-05-08	NUG	Patent has lapsed	Ref document number: 8204792-9 Format of ref document f/p: F

Date

Code

Title

Description

1995-01-31

NAL

Patent in force

Ref document number: 8204792-9

Format of ref document f/p: F

1995-05-08

NUG

Patent has lapsed